DK3248597T3 - Terapeutisk middel til sensorineuralt høretab - Google Patents
Terapeutisk middel til sensorineuralt høretab Download PDFInfo
- Publication number
- DK3248597T3 DK3248597T3 DK16740038.1T DK16740038T DK3248597T3 DK 3248597 T3 DK3248597 T3 DK 3248597T3 DK 16740038 T DK16740038 T DK 16740038T DK 3248597 T3 DK3248597 T3 DK 3248597T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic agent
- hearing loss
- sensorineural hearing
- sensorineural
- loss
- Prior art date
Links
- 206010011891 Deafness neurosensory Diseases 0.000 title 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 title 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015007849 | 2015-01-19 | ||
| PCT/JP2016/050861 WO2016117431A1 (ja) | 2015-01-19 | 2016-01-13 | 内耳性難聴治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3248597T3 true DK3248597T3 (da) | 2024-04-08 |
Family
ID=56416978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16740038.1T DK3248597T3 (da) | 2015-01-19 | 2016-01-13 | Terapeutisk middel til sensorineuralt høretab |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11058669B2 (da) |
| EP (2) | EP3248597B1 (da) |
| JP (2) | JP6716139B2 (da) |
| DK (1) | DK3248597T3 (da) |
| ES (1) | ES2928593T3 (da) |
| FI (1) | FI3248597T3 (da) |
| PT (1) | PT3248597T (da) |
| WO (1) | WO2016117431A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101785455B1 (ko) * | 2016-03-16 | 2017-11-20 | 전남대학교산학협력단 | 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물 |
| CA3064018A1 (en) * | 2017-05-26 | 2018-11-29 | Kite Pharma, Inc. | Methods of making and using embryonic mesenchymal progenitor cells |
| JP6999896B2 (ja) | 2017-09-21 | 2022-01-19 | 学校法人慶應義塾 | 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物 |
| CN108310386A (zh) * | 2018-04-09 | 2018-07-24 | 南方医科大学 | mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途 |
| JP2023106640A (ja) * | 2020-06-09 | 2023-08-02 | 株式会社オトリンク | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 |
| KR20220146349A (ko) * | 2021-04-23 | 2022-11-01 | 연세대학교 산학협력단 | 오토파지 활성화제를 유효성분으로 포함하는 비증후군성 상염색제-우성 난청의 예방 또는 치료용 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3963495B2 (ja) | 1995-05-22 | 2007-08-22 | 生化学工業株式会社 | アポトーシス惹起抑制剤 |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
| JP2003519655A (ja) | 2000-01-14 | 2003-06-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | リンパ増殖症候群の緩和および阻害のためのｏ−メチル化ラパマイシン誘導体 |
| JP2004123713A (ja) * | 2002-08-05 | 2004-04-22 | Mitsubishi Pharma Corp | 突発性難聴の予防及び／又は治療のための医薬 |
| JP2004099537A (ja) * | 2002-09-10 | 2004-04-02 | Sanwa Kagaku Kenkyusho Co Ltd | 難聴疾患の予防又は治療剤 |
| WO2005009287A2 (en) | 2003-07-21 | 2005-02-03 | University Of Maryland, Baltimore | Drug delivery to the inner ear and methods of using same |
| KR20080018874A (ko) | 2005-04-27 | 2008-02-28 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | 인간 질병과 관련된 돌연변이 단백질의 분해 촉진을 위한물질 및 방법 |
| US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
| EP2155681B1 (en) * | 2007-05-17 | 2018-05-02 | Athenex, Inc. | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| BRPI0915770A2 (pt) | 2008-07-14 | 2015-11-03 | Otonomy Inc | composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos |
| CN102612564B (zh) | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
-
2016
- 2016-01-13 ES ES17187312T patent/ES2928593T3/es active Active
- 2016-01-13 PT PT167400381T patent/PT3248597T/pt unknown
- 2016-01-13 JP JP2016570589A patent/JP6716139B2/ja active Active
- 2016-01-13 EP EP16740038.1A patent/EP3248597B1/en active Active
- 2016-01-13 DK DK16740038.1T patent/DK3248597T3/da active
- 2016-01-13 EP EP17187312.8A patent/EP3295939B1/en active Active
- 2016-01-13 FI FIEP16740038.1T patent/FI3248597T3/fi active
- 2016-01-13 WO PCT/JP2016/050861 patent/WO2016117431A1/ja active Application Filing
- 2016-01-13 US US15/544,419 patent/US11058669B2/en active Active
-
2017
- 2017-05-24 JP JP2017102712A patent/JP6708346B2/ja active Active
- 2017-07-19 US US15/654,267 patent/US11013725B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11013725B2 (en) | 2021-05-25 |
| WO2016117431A1 (ja) | 2016-07-28 |
| EP3248597B1 (en) | 2024-03-13 |
| EP3295939B1 (en) | 2022-09-21 |
| ES2928593T3 (es) | 2022-11-21 |
| EP3248597A1 (en) | 2017-11-29 |
| US20170333403A1 (en) | 2017-11-23 |
| US11058669B2 (en) | 2021-07-13 |
| US20170340586A1 (en) | 2017-11-30 |
| EP3248597A4 (en) | 2018-10-10 |
| EP3295939A1 (en) | 2018-03-21 |
| PT3248597T (pt) | 2024-03-25 |
| JP6708346B2 (ja) | 2020-06-10 |
| FI3248597T3 (fi) | 2024-04-17 |
| JP6716139B2 (ja) | 2020-07-01 |
| JP2017200923A (ja) | 2017-11-09 |
| JPWO2016117431A1 (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY4489S (es) | Auriculares | |
| BR112018009951A2 (pt) | fármaco oftálmico | |
| DK3356313T3 (da) | 2-perfluorhexyloktan til oftalmisk indgivelse | |
| DK3013070T3 (da) | Høresystem | |
| DK3289080T3 (da) | Genterapi til autosomalt dominante sygdomme | |
| DK3337185T3 (da) | Knogleledningshøjtaler | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3006079T3 (da) | Høresystem | |
| DK3474804T3 (da) | Medicinsk forbinding | |
| DK3513569T3 (da) | Øretelefon | |
| DK3001700T3 (da) | Positioneret høresystem | |
| DK3248597T3 (da) | Terapeutisk middel til sensorineuralt høretab | |
| DK3280158T3 (da) | Høreapparat | |
| DK3304934T3 (da) | Høreapparat | |
| DK3373874T3 (da) | Medicinsk forbinding | |
| DK3308781T3 (da) | Antihypertensivt middel | |
| DE112016003293A5 (de) | Feuerlöscher | |
| DK3474803T3 (da) | Medicinsk forbinding | |
| DK3315131T3 (da) | Terapeutisk middel mod fibrose | |
| DK3325027T3 (da) | Medicinsk implantat | |
| DK3294769T3 (da) | Behandling for multipelt myelom (mm) | |
| DK3395081T3 (da) | Høreapparattilpasningssystem | |
| DK3307184T3 (da) | Implantatfjerner | |
| DK3182728T3 (da) | Høreapparat | |
| EP3308662A4 (en) | FACIAL MASK STRUCTURE |